Rapamycin is arguably the most promising longevity compound identified to date. Originally developed as an immunosuppressant, it is the only drug to consistently extend lifespan across multiple animal models — and has become a focus of intense research in human longevity medicine.
What Does the Research Say?
The landmark ITP (Interventions Testing Program) study at the NIA found rapamycin extended median lifespan by 9–14% in mice — even when started at an age equivalent to 60 human years. The mechanism centers on mTOR (mechanistic target of rapamycin) inhibition. mTOR is a master regulator of cellular growth, autophagy, and protein synthesis. Chronic mTOR overactivation drives accelerated aging through reduced autophagy, senescent cell accumulation, and impaired cellular quality control.
Human clinical trials, including studies by Dr. Joan Mannick, have demonstrated that low-dose intermittent rapamycin improved immune function in older adults without significant immunosuppression at the doses used. Multiple trials including PEARL and REALM are now investigating longevity endpoints in humans.
Key Findings
- Only drug proven to extend lifespan in mice even when treatment starts in old age
- Inhibits mTOR-C1, restoring autophagy and cellular quality control mechanisms
- Low-dose intermittent use (5–6mg once weekly) shows favorable safety profile in human studies
- Multiple ongoing human phase 2 trials (PEARL, REALM) investigating longevity endpoints
Practical Takeaway
Rapamycin for longevity is available in some clinics as an off-label prescription. Typical longevity protocols use 5–6mg once weekly — significantly lower than immunosuppressive doses. Medical supervision including baseline labs is essential; this is not a self-administered supplement.